FLNA

BPGbio Presents Key Advances in its Oncology Pipeline related to the NAi Interrogative Biology Platform

Retrieved on: 
Friday, April 5, 2024
Oncology, Health, Technology, Health Technology, Artificial Intelligence, Pharmaceutical, Biotechnology, UBE2M, Oak Ridge National Laboratory, Neurology, Prostate cancer, Serum, FLNA, Drug discovery, Patient, GBM, Hospital, Research, Cancer, University, Hope, Deep learning, AACR, Clinical trial, Drug development, University of Tennessee, Immune system, Stanford University, Multimedia, Netherlands Architecture Institute

BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.

Key Points: 
  • BPGbio, Inc., a leading biology-first AI-powered biopharma that focuses on oncology, neurology, and rare diseases, today announced the application of its NAi Interrogative Biology® Platform across several drug and diagnostic applications, following successful collaborations with Stanford University, University of Tennessee, Oak Ridge National Laboratory, and several leading hospitals across Mexico.
  • The company will present four posters showcasing these research collaborations and provide updates on other internal research activities at the American Association for Cancer Research (AACR) Annual Meeting being held April 5-10, 2024, in San Diego, Calif.
  • This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240405006693/en/
    A graphical representation of BPGbio's NAi Interrogative Biology Platform (Graphic: Business Wire)
    New data further validating the mitochondrial-centric effect of BPM31510 on the immune system.

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

Retrieved on: 
Wednesday, February 28, 2024
Research, ARIA, FLNA, Drug development, ADAS, Exercise, ADAS-Cog, Private law, Mass spectrometry, Criterion, CDR, Bawskee 3.5, Protein, Intellectual property, Patient, Plasma, Cassava Sciences, PET, MRI, City University, Hyperkinesia, Cerebrospinal fluid, Edema, Cassava, Memory, Insulin, G&A, Tablet, Brain, City, CUNY, SAP, Calendar, Completion, Safety, Clinical, Knowledge, Alzheimer's disease, Magnetic resonance imaging, Blood, FDA, Ageing, Food, Data, Lymphocyte, Medicine, DSMB, Pharmaceutical industry

AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.

Key Points: 
  • AUSTIN, Texas, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today reported financial and operating results for the full year ended December 31, 2023 and presented corporate updates.
  • Net cash used in operations full-year 2023 was $82.0 million, consistent with previous guidance.
  • (This amount is not included in the above cash and cash equivalents at December 31, 2023.)
  • Recent corporate highlights include the following:
    In January 2024, we completed a dividend distribution of common stock warrants to shareholders.

Statement by Cassava Sciences Regarding an Internal CUNY Report Leaked to the Press

Retrieved on: 
Friday, October 13, 2023
Congress, City University of New York, Environmental Molecular Sciences Laboratory, City University, International Journal of Molecular Sciences, University, Epilepsy, Cassava Sciences, CUNY, FLNA, Phosphorylation, Yale University, Canadian International Council, Science Translational Medicine, Research, Pharmaceutical industry, Management, Cassava, Endocrinology, Science

CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of research misconduct.

Key Points: 
  • CUNY’s report finds that internal record-keeping failures “prevented us [CUNY] from making an objective assessment” of research misconduct.
  • AUSTIN, Texas, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today issued the following statement regarding an internal report purportedly prepared by City University of New York (CUNY).
  • The leak of the CUNY report was preceded by a 40% increase in short selling activity in the stock of Cassava Sciences.
  • CUNY has not responded to an inquiry Cassava Sciences made yesterday regarding the authenticity of the leaked report.

Schneider named a 2023 Top Food Chain Provider

Retrieved on: 
Friday, October 13, 2023
EV, Electric Vehicles, Automotive, Trucking, Supply Chain Management, Food, Beverage, Logistics, Transport, Retail, Food chain, NYSE, PepsiCo, Schneider National, Snack, FLNA, Freightliner, Schneider, FSA, BEV, Intermodal transport, Rail freight transport, Cargo

Schneider National, Inc. (NYSE: SNDR), a premier multimodal provider of transportation, intermodal and logistics services, has been selected as a 2023 Top Food Chain Provider by Food Chain Digest, the official magazine of the Food Shippers of America (FSA).

Key Points: 
  • Schneider National, Inc. (NYSE: SNDR), a premier multimodal provider of transportation, intermodal and logistics services, has been selected as a 2023 Top Food Chain Provider by Food Chain Digest, the official magazine of the Food Shippers of America (FSA).
  • Schneider was named to this elite list for the carrier’s quality service and capabilities, alongside its dedication to solving customer challenges and accomplishing company business goals.
  • Receiving this recognition is an accomplishment for our team and testament to the service they deliver every day.”
    The companies named to the Top Food Chain Providers list were evaluated by the staff at Food Chain Digest and voted on by over 6,000 professionals in the food supply chain, transportation, warehousing and distribution industry segments.
  • Each year, Schneider helps more than 425 food and beverage customers solve their shipping challenges by providing transportation solutions and services for their entire supply chain.

Cassava Sciences Announces Science Publication That Confirms Mechanism of Action of Simufilam, a Novel Drug Candidate for People with Alzheimer’s Disease

Retrieved on: 
Monday, September 11, 2023
Epilepsy, Yale University, University, Phosphorylation, Cassava, Cassava Sciences, Research, Doctor of Philosophy, Dementia, CUNY School of Labor and Urban Studies, CNRS, Patient, Canadian International Council, SPA, FLNA, Seizure, Mouse, CUNY School of Medicine, International Journal of Molecular Sciences, University of Milan, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Environmental Molecular Sciences Laboratory, Food, Medicine, Pharmaceutical industry, Medical imaging, Neuroscience, Inserm

AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.

Key Points: 
  • AUSTIN, Texas, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a biotechnology company focused on Alzheimer’s disease, today announced the publication of new research that confirms the biological activity of simufilam.
  • Simufilam is Cassava Sciences’ novel drug candidate for people with Alzheimer’s disease dementia and is currently under evaluation in a pair of global Phase 3 clinical trials.
  • Cassava Sciences believes this protein interaction underlies simufilam’s mechanism of action in Alzheimer’s disease.
  • Cassava Sciences is evaluating simufilam oral tablets for Alzheimer’s disease dementia in two global Phase 3 clinical studies.

New Data by Academic Researchers Highlights Biological Activity of Simufilam on Filamin A

Retrieved on: 
Monday, May 8, 2023
Adenoma, Phosphorylation, Prior, Cassava Sciences, Research, Publication, European Society of Endocrinology, FLNA, European Society for Primary Immunodeficiencies, FDA, Mobile phone, Pharmaceutical industry

AUSTIN, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein.

Key Points: 
  • AUSTIN, Texas, May 08, 2023 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced new data from European researchers that highlight the bioactivity of simufilam on the filamin A (FLNA) protein.
  • New in vitro data now show that simufilam can reverse this FLNA alteration in pituitary tumor cells, leading to improved cell signaling.
  • This bioactivity is thematically consistent with the proposed mechanism of action of simufilam in Alzheimer’s disease, namely, simufilam reverses a filamin A alteration.
  • Today’s new data by researchers in Europe shows a functional interaction between simufilam, FLNA and somatostatin receptors.

Frito-Lay North America Completes First Third-Party Electric Vehicle Shipment in Continued Effort to Decarbonize Supply Chain

Retrieved on: 
Thursday, April 13, 2023
Partnership, EV, Frito-Lay, PEP, Carbon, PepsiCo, Dallas–Fort Worth metroplex, Schneider, FLNA, Growth, Transport, NYSE, Renewable energy, Freightliner

PLANO, Texas, April 13, 2023 /PRNewswire/ -- Frito-Lay North America (FLNA) today announces its first-ever third-party shipment on an electric vehicle with Schneider National Inc. (NYSE: SNDR), a premier multimodal provider of transportation, intermodal and logistics services. This is the first third-party transportation shipment on an electric vehicle (EV) for PepsiCo globally and establishes FLNA and its beloved snack products as the first to contract transport on Schneider's electric truck fleet of Freightliner eCascadias.

Key Points: 
  • This is the first third-party transportation shipment on an electric vehicle (EV) for PepsiCo globally and establishes FLNA and its beloved snack products as the first to contract transport on Schneider's electric truck fleet of Freightliner eCascadias.
  • "As a company with massive scale, Frito-Lay looks for opportunities to create positive change – but we can't do it alone.
  • Frito-Lay's partnership with Schneider lays important groundwork for an expansion of low- or zero-emissions vehicle use within its third-party transportation footprint.
  • To serve the company's hometown market of Dallas-Fort Worth, Frito-Lay also introduced 40 100% electric, zero-emissions route trucks in 2022.

PepsiCo Debuts New Customer Sustainability Platform Designed To Deliver Critical Solutions Most Needed by Customers

Retrieved on: 
Wednesday, April 12, 2023
Paris Agreement, Pepsi, Senior, Partner, Farmer, Electricity, SodaStream, NZE, CFG Bank Arena, Soil, Investment, Transport, Paris, RPET, PEP, Frito-Lay, Hearing, Oak View Group, Climate, Erosion, Tesla, Plastic, Carbon accounting, PFNA, Southeastern Massachusetts Agricultural Partnership, Tomorrow, Practical Farmers of Iowa, Climate change, Glass, Partnership, Food, Agriculture, Water quality, PET, GHG, PepsiCo, Regenerative agriculture, Professional, FLNA, TURN, Health, Marketing, Renewable energy, Aquafina

PURCHASE, N.Y., April 12, 2023 /PRNewswire/ -- Today, PepsiCo announced pep+ Partners for Tomorrow, a new platform that delivers solutions that aim to support its customers in achieving their sustainability goals. With the launch of Partners for Tomorrow, PepsiCo is proud to continue to assist and support customers as they look for custom solutions to achieve their own sustainability goals. The initial launch will focus on U.S. customers with plans to expand the program to key global markets by 2024.

Key Points: 
  • PURCHASE, N.Y., April 12, 2023 /PRNewswire/ -- Today, PepsiCo announced pep+ Partners for Tomorrow, a new platform that delivers solutions that aim to support its customers in achieving their sustainability goals.
  • With the launch of Partners for Tomorrow, PepsiCo is proud to continue to assist and support customers as they look for custom solutions to achieve their own sustainability goals.
  • The initial launch will focus on U.S. customers with plans to expand the program to key global markets by 2024.
  • Partners for Tomorrow will bring PepsiCo's comprehensive customer sustainability offerings under a single platform to deliver the critical solutions most needed by the company's partners and will work directly with them to implement the initiatives.

PEPSICO BEVERAGES & FRITO-LAY ANNOUNCE $3.3 MILLION IN WATER REPLENISHMENT PROJECTS TO DRIVE PROGRESS TOWARD PEPSICO POSITIVE WATER POSITIVE GOALS

Retrieved on: 
Tuesday, March 14, 2023
PepsiCo, University, Pulse, Groundwater, Drink, City, Investment, Water, Reclaimed water, Fresh water, Commerce, The Sapphire Necklace, Floridan aquifer, Wetland, FLNA, Plant, Biodiversity, Frito-Lay, Partnership, American Water, U.S. Chamber of Commerce Building, Renewable energy, Hunting, Veolia, Rangia

PURCHASE, N.Y., March 14, 2023 /PRNewswire/ -- PepsiCo Beverages North America (PBNA) and Frito-Lay North America (FLNA) today announced a commitment of $3.3 million in funds toward water replenishment projects across North America. These projects aim to advance PepsiCo's ambitious effort to become Net Water Positive by 2030, which includes reducing absolute water use and replenishing back into the local watershed more than 100% of the water used at company-owned and third-party sites in high water-risk areas.

Key Points: 
  • PURCHASE, N.Y., March 14, 2023 /PRNewswire/ -- PepsiCo Beverages North America (PBNA) and Frito-Lay North America (FLNA) today announced a commitment of $3.3 million in funds toward water replenishment projects across North America.
  • This project aims to provide an additional 2,000 acre-feet1 per year of water, starting this spring, for 10 consecutive years.
  • "The City of Winter Haven, Florida, has been a leader in integrated water management practices for over 20 years.
  • In Galveston, Texas, PepsiCo's $1.2 million investment is part of the company's North American Water Replenishment program, bringing together the expertise of PBNA and FLNA to scale investment and impact of water replenishment projects where facilities are co-located in water scarce areas.

Cassava Sciences Announces Completion of Dosing in Open-label Study of Simufilam for Alzheimer’s Disease

Retrieved on: 
Tuesday, December 6, 2022
Geography, Patient, ADAS, Annual report, Food, Safety, Science, FLNA, News, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, SPA, Cognition, Neurodegeneration, Dementia, Data analysis, Research, Risk, COVID-19, Brain, Drug development, Pharmaceutical industry

AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzheimer’s disease.

Key Points: 
  • AUSTIN, Texas, Dec. 06, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company, today announced the completion of drug administration in an open-label study of simufilam for Alzheimer’s disease.
  • Simufilam is Cassava Sciences’ oral drug candidate for Alzheimer’s disease dementia.
  • Cassava Sciences may announce study results approximately year-end 2022, pending completion of a study report by outside biostatisticians.
  • I believe Cassava Sciences may be at the forefront of this effort to innovate.”
    Cassava Sciences is evaluating simufilam for Alzheimer’s disease dementia in two Phase 3 clinical studies.